AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RAPP

PAUL STEVEN M purchased $974K of RAPP (indirect holdings)

PAUL STEVEN M purchased 35,714 indirectly-held shares of Rapport Therapeutics, Inc. (RAPP) at $27.28 ($0.97M total) on 2026-10-22.

Original reporting
SEC EDGAR · PAUL STEVEN M
Published Oct 22, 2026, 8:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RAPP
Bullish
high confidence
Mentioned
$RAPP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RAPPBullishLow
01

Why it matters

The director's purchase adds credibility to the company and may attract short‑term interest.

02

Market read

A director's $974K purchase is a modest but noteworthy insider signal for RAPP.

03

What to watch

Potential upcoming clinical data or financing events not disclosed in the filing.

Relevance 6/10Novelty 4/10Timing: today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$RAPPBullishHigh confidence
Context

Director Paul Steven M bought 35,714 shares of Rapport Therapeutics at $27.28, totaling $974,278, increasing his holdings to 77,380 shares.

Expected impact

modest upward pressure as the market prices in the insider buying

Evidence & confidence

The purchase is sizable for a micro‑cap and comes from a director, indicating potential upside perception.

Market effects

Sector

Limited; may slightly boost sentiment in the biotech/therapeutics sector.

Regional

Minimal, confined to U.S. small‑cap investors.

Global

Low; no broader market effect.

Counterpoint

What could challenge this read

The purchase could be routine portfolio rebalancing rather than a strong bullish signal.

Key entities

  • company
    Rapport Therapeutics, Inc.

    Biotech firm developing therapeutic candidates.

  • person
    Paul Steven M

    Director of Rapport Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RAPP insider trading history →

Related articles

$RAPPMed

Rapport Therapeutics 3Q 2026: Revenue $0 Net loss $40.2M, EPS $(0.84) — 10-Q Summary

Rapport Therapeutics reported no revenue and a net loss of $40.2M in 3Q 2026, widening from a $26.9M loss in the prior-year quarter. Diluted EPS was $(0.84). The company began Phase 3 trials for RAP-219 in epilepsy and plans further trials in 2027. Collaboration revenue from Tenacia was $20M for the nine months. According to the company, they deferred one program and prioritized another.

tradingview.com
$RAPPHighAI 9/10

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label

SEC EDGAR 8-K
$RAPPMedAI 9/10

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

Rapport Therapeutics (RAPP) closed public offerings of 9.76M shares of common stock at $21.00 per share, $172.5M in convertible notes, and a concurrent private placement of 1.43M shares. Total net proceeds are approximately $410.7M. Proceeds will fund clinical trials, R&D, and general corporate purposes. The notes have a 2.25% interest rate and mature in 2032.

finance.yahoo.com